Get the Stockscreener App
144.98
1.38%
1.98
Pre-market:
145.48
0.50
+0.34%
Protagonist Therapeutics Inc stock is traded at $144.98, with a volume of 735.08K.
It is up +1.38% in the last 24 hours and down -6.05% over the past month.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
See More
Previous Close:
$143.00
Open:
$143.22
24h Volume:
735.08K
Relative Volume:
1.13
Market Cap:
$9.38B
Revenue:
$74.06M
Net Income/Loss:
$-114.71M
P/E Ratio:
-80.37
EPS:
-1.8039
Net Cash Flow:
$-117.90M
1W Performance:
-1.89%
1M Performance:
-6.05%
6M Performance:
+46.64%
1Y Performance:
+133.09%
1-Day Range:
$141.09
$145.37
1-Week Range:
$140.44
$147.99
52-Week Range:
$61.95
$160.81
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
144.98 | 9.59B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-26 | Upgrade | Goldman | Neutral → Buy |
| May-21-26 | Initiated | Wolfe Research | Outperform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com Australia
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares - MarketBeat
Protagonist Therapeutics CEO sells $18.2m in shares - Investing.com India
Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan - Stock Titan
Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock - Moomoo
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com Nigeria
Protagonist Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com Nigeria
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
Protagonist Therapeutics authorizes $300 million buyback plan - investing.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
Up to $300 million could go toward buying back shares at Protagonist Therapeutics. - Stock Titan
Protagonist Therapeutics (PTGX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? - Yahoo Finance
Protagonist Therapeutics (PTGX) Stock Looks Fully Priced After Its 7x Run - simplywall.st
Research Analysts Offer Predictions for PTGX Q1 Earnings - marketbeat.com
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 - ACCESS Newswire
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - The Globe and Mail
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News - Yahoo Finance
Protagonist Therapeutics (NASDAQ:PTGX) Gets A Higher Price Target - Kalkine Media
BMO raises Protagonist Therapeutics price target on Mimrylo approval By Investing.com - Investing.com Canada
PTGX Maintained by BMO Capital -- Price Target Raised to $190 - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $190.00 Price Target at BMO Capital Markets - MarketBeat
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call - Yahoo Finance
Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval? - Yahoo Finance
PTGX Maintained by Citigroup -- Price Target Raised to $182 - GuruFocus
Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says - marketscreener.com
Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept - marketscreener.com
Protagonist Therapeutics stock rating maintained at Buy by Clear Street - Investing.com
Jefferies reiterates Protagonist Therapeutics stock rating on Mimrylo label strength - Investing.com Canada
Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform By Investing.com - Investing.com Nigeria
Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform - Investing.com
Protagonist to change PV narrative with Takeda Mimrylo win? - BioWorld News
PTGX Maintained by HC Wainwright & Co. -- Price Target Raised to $170 - GuruFocus
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia VeraSlideshow (NASDAQ:PTGX) 2026-08-31 - Seeking Alpha
132,351 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Legal & General Group Plc - MarketBeat
Protagonist Therapeutics Inc. (PTGX) Peer Comparison – Compare with Others - Value Research
Wellington Management Group LLP Sells 182,863 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Hsbc Holdings PLC Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - marketbeat.com
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Alyeska Investment Group L.P. - MarketBeat
58,059 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Twin Lakes Capital Management LLC - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 108,555 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PATEL DINESH V PH D | President and CEO |
Sep 08 '26 |
Option Exercise |
21.58 |
54,174 |
1,169,075 |
577,142 |
| PATEL DINESH V PH D | President and CEO |
Sep 10 '26 |
Option Exercise |
21.58 |
7,278 |
157,059 |
530,246 |
| PATEL DINESH V PH D | President and CEO |
Sep 09 '26 |
Sale |
146.18 |
63,548 |
9,289,447 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Sep 08 '26 |
Sale |
145.87 |
54,174 |
7,902,361 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Sep 10 '26 |
Sale |
144.10 |
7,278 |
1,048,760 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Aug 10 '26 |
Option Exercise |
21.58 |
65,761 |
1,419,122 |
589,239 |
| PATEL DINESH V PH D | President and CEO |
Aug 11 '26 |
Option Exercise |
21.58 |
34,239 |
738,878 |
557,717 |
| PATEL DINESH V PH D | President and CEO |
Aug 10 '26 |
Sale |
149.11 |
65,761 |
9,805,623 |
523,478 |
| PATEL DINESH V PH D | President and CEO |
Aug 11 '26 |
Sale |
148.52 |
34,239 |
5,085,176 |
523,478 |
0.05%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):